Bulling S , Schicker K , Zhang YW , Steinkellner T , Stockner T , Gruber CW , Boehm S , Freissmuth M , Rudnick G , Sitte HH , Sandtner W .

DA007259 NIDA NIH HHS , R01 DA007259 NIDA NIH HHS , F 3506 Austrian Science Fund FWF, R01 DA008213 NIDA NIH HHS , W 1232 Austrian Science Fund FWF

	FIGURE 1. Ibogaine inhibition of transport and binding by SERT and DAT. a, [3H]5-HT influx into cells stably expressing hSERT was measured in the absence (filled circles) or presence (open circles) of 10 μm ibogaine. The incubation time was 1 min and nonspecific uptake was measured in the presence of 10 μm paroxetine. b, [3H]MPP+ influx into cells stably expressing hDAT was measured as above using a 3-min incubation in the absence (filled circles) or presence (open circles) of 10 μm ibogaine. Nonspecific uptake was determined in the presence of 10 μm mazindol and was subtracted to the given values. The data in a and b are shown in form of Eadie-Hofstee plots, where the intercept on the y axis is equivalent to the Vmax and Km is given by the negative of the slope. For SERT the slopes at 0 and 10 μm ibogaine were statistically equivalent (p = 0.90 F test) and therefore globally fit with −6.18 ± 0.33 μm with a y intercepts of 15.51 ± 0.57 pmol/106 cells/min (R2 = 0.99) at 0 μm ibogaine and 7.92 ± 0.38 pmol/106 cells/min (R2 = 0.95) at 10 μm ibogaine. For DAT the slopes were also equivalent (p = 0.24 F test) and fit with −20.37 ± 0.8 μm with a y intercept of 272.30 ± 8.64 pmol/106 cells/min (R2 = 0.99) at 0 μm ibogaine and 191.70 ± 6.75 pmol/106 cells/min (R2 = 0.97) at 10 μm ibogaine. c–f, competition between ibogaine and 2 nm [3H]imipramine bound to SERT (c and d) and between ibogaine and 10 nm [3H]WIN35,428 bound to DAT (e and f) in the presence and absence of 10 μm 5-HT and DA, respectively. c, [3H]imipramine was displaced by ibogaine with an IC50 of 1.94 μm [1.71–2.21] (R2 = 0.95) in the absence of 5-HT and with an IC50 of 5.76 μm [3.72–9.00] (R2 = 0.85) in the presence of 10 μm 5-HT. 10 μm 5-HT reduced initial binding to 47% (95% confidence interval, 43–51). d, Dixon plot obtained by transformation of c. The slopes in d are 0.37 μm−1 (0.35–0.40) and are not statistically different (p = 0.38). e, [3H]WIN35,428 was displaced by ibogaine with an IC50 of 12.33 μm (10.46–14.54) (R2 = 0.99) in the absence of DA and with an IC50 of 23.14 μm (17.49–30.60) (R2 = 0.98) in the presence of 10 μm DA. 10 μm DA reduced initial binding to 57% (54–60). f, Dixon plot obtained by transformation of e. The slopes in f are 0.076 μm−1 (0.059–0.093) and are not statistically different (p = 0.50).
	FIGURE 2. Ibogaine does not elicit an amphetamine-like releasing action in SERT and DAT. a and b, effect of ibogaine and PCA (a) or d-amphetamine (b) in a release assay. CAD cells transiently transfected with hSERT (a) or hDAT (b) were preloaded with [3H]5-HT or [3H]DA, and superfused with buffer. 2-min fractions were collected. Ibogaine (50 μm), PCA (3 μm), or d-amphetamine (3 μm) were added after six fractions (at time point 10) and five more 2-min fractions were collected (time points 12–20). Data are fractional release per 2 min in percent. Experiments were performed in quadruplicates; n = 2 (a), n = 3 (b).
	FIGURE 3. Inhibition of substrate transport and induced currents by ibogaine. a, for transport, HEK-293 cells expressing hSERT (filled circles) or hDAT (open circles) were incubated with either 0.1 μm [3H]5-HT or 0.01 μm [3H]MPP+ for 1 or 3 min, respectively, in the presence of the indicated concentrations of ibogaine. The IC50 values for ibogaine inhibition of transport were 6.43 μm (5.03–8.21) R2 = 0.91 for SERT and 23.17 μm (17.76–30.23) R2 = 0.78 for DAT. b, measurements of substrate-induced currents were performed using two electrode voltage-clamp with X. laevis oocytes expressing hSERT (filled circles) or hDAT (open circles), clamped to a holding potential of −60 mV. Current was induced by addition of 10 μm 5-HT or 3 μm DA, respectively, and ibogaine was present at the indicated concentrations. The IC50 values for ibogaine inhibition of he substrate-induced current were 3.44 μm (3.10–3.86) R2 = 0.98 for SERT and 22.33 μm (19.32–25.80) R2 = 0.95 for DAT. c, current traces for 5-HT-induced currents and ibogaine inhibition of hSERT. Pulses of 10 μm 5-HT together with the indicated concentrations of ibogaine were applied to X. laevis oocytes expressing hSERT and the substrate-induced currents were measured by two electrode voltage-clamp. Data from this representative experiment and other similar trials were combined by calculating mean currents normalized to maximal substrate-induced inward current at 10 μm 5-HT in the absence of ibogaine, ± S.E., n = 6. The data shown in panel B (filled circles) shows the mean ± S.E. of these experiments. D, current traces for ibogaine inhibition of DAT currents induced by 3 μm DA, measured as in c using oocytes expressing hDAT.
	FIGURE 4. Reactivity of the DAT cytoplasmic pathway is increased by ibogaine. Ser-262 in DAT, corresponding to the cytoplasmic pathway residue Ser-277 identified in SERT, was mutated to cysteine in the X5C background (42). Membrane fragments from HeLa cells expressing DAT X5C-S262C were treated with the indicated concentrations of MTSEA for 15 min in the presence or absence of 10 μm cocaine, 10 μm DA, or 20 μm ibogaine as indicated, and then assayed for residual [3H]CFT binding as previously described for SERT (43, 54). From the MTSEA concentrations required for half-maximal inactivation, the rate constants for inactivation were 82 ± 3 s−1 m−1 for MTSEA alone, 13 ± 2 s−1 m−1 in the presence of cocaine, 419 ± 36 s−1 m−1 with DA present, and 348 ± 95 s−1 m−1 in the presence of ibogaine. Results are mean ± S.E. from 3 independent experiments.
	FIGURE 5. Ibogaine blocks substrate-induced currents only from the extracellular side. a, single hSERT expressing cells were voltage clamped to −70 mV using the whole cell patch clamp configuration and continuously superfused with buffer solution as described under “Experimental Procedures.” A 6-s pulse of 10 μm p-chloroamphetamine (a SERT substrate) was applied either in the absence (lower trace) or presence (upper trace) of 10 μm ibogaine in the extracellular medium. b, single hSERT expressing cells were voltage clamped and stimulated with PCA as in a, but with a pipette solution containing 100 μm ibogaine. c, single hSERT expressing cells were voltage clamped as in a and b and stimulated with a range of PCA concentrations. Once per minute they were challenged with a 5-s pulse of 10 μm PCA, either in the absence (filled circles) or after a 10-s pre-application of either 1 or 10 μm ibogaine (open circles and filled squares, respectively). Ibogaine reduced the maximal charge transfer to 0.44 ± 0.04 at 1 μm (n = 5) and 0.09 ± 0.08 at 10 μm (n = 5), whereas the EC50 of PCA was not changed (0.72 μm (0.34–1.55 μm) control (ctl) (n = 10); 0.62 μm (0.23–1.70 μm) at 1 μm ibogaine (n = 5); 0.52 μm (0.44 nm to 62.14 μm) at 10 μm ibogaine (n = 5). d, ibogaine did not influence the concentration response when present in the intracellular pipette solution. Single hSERT expressing cells were voltage clamped and stimulated with PCA as in c using either normal pipette solution (filled circles) or pipette solution containing 100 μm ibogaine (open circles). Ibogaine did not change the EC50 of PCA when applied from the inside (0.66 μm (0.55–0.79 μm) under control (n = 10); 0.80 μm (0.69–0.93 μm) with 100 μm ibogaine inside, n = 10). The inset shows a comparison of the current amplitudes induced by 10 μm PCA both in the absence (−13.3 pA ± 1.4 pA, filled column) and presence of 100 μm internal ibogaine (−11.7 ± 1.1 pA, open column) (p = 0.26, Mann-Whitney U test).
	FIGURE 6. Kinetics of current block by ibogaine and cocaine. Single hSERT expressing cells were voltage clamped to −70 mm using the whole cell patch clamp technique. Cells were continuously superfused with buffer solution. a and b, for the evaluation of blocking kinetics cells were challenged with 5-HT (10 μm). 2 s after 5-HT addition, the blocking agent (ibogaine (a) or cocaine (b)) was applied for 10 s and then washed away for 60 s in the presence of 5-HT. c, comparison of the blocking kinetics of ibogaine (10 μm) and cocaine (10 μm). Gray lines indicate representative traces, and black lines show fits to the traces. d, analysis of the blocking kinetics of ibogaine (filled circles) and cocaine (open circles) over a range of concentrations. Rate constants for the development of the block were calculated over the concentration range and plotted against concentration. The black lines are linear fits through the data points and the gray areas indicate 95% confidence intervals. The slope for ibogaine was significantly different from zero (p < 0.0001 F test), 7.6 × 104 ± 0.4 × 104 s−1 m−1, and the y intercept was 5.3 ± 0.5 s−1. The slope for cocaine was 3 × 103 ± 2 × 103 s−1 m−1, which was not significantly different from zero (p = 0.16 F test), and the y intercept was 1.5 ± 0.4 s−1.
	FIGURE 7. A kinetic model for cocaine and ibogaine inhibition of substrate-induced currents in SERT. a, the model was based on a kinetic model for 5-HT-induced currents (18). KD values of 1 μm were used for both cocaine (coc) and ibogaine (ibo) (4, 36). 5-HT is represented as S. Although cocaine binds in the absence of NaCl, and its affinity is not increased by Cl− (36), binding was arbitrarily assigned to the ToNaCl intermediate to avoid undue complexity in the model. See supplemental data for a more complete analysis of the model. The slow K+-independent conversion of Ti to To is likely to represent H+ export as described previously (45). The conducting state is shown as TiKCond (18). b and c, simulations based on the model in a. b, simulated current amplitudes as a function of substrate concentration in the absence and presence of 1 and 10 μm ibogaine. c, simulated association rate constants (kapp) for ibogaine and cocaine as a function of their concentration.

Andersen, Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. 2009, Pubmed

Andersen, Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. 2009, Pubmed
Andersen, Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter. 2010, Pubmed
Baumann, In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. 2001, Pubmed
Beuming, The binding sites for cocaine and dopamine in the dopamine transporter overlap. 2008, Pubmed
Boehm, ATP stimulates sympathetic transmitter release via presynaptic P2X purinoceptors. 1999, Pubmed
Czech, Cytochalasin B-sensitive 2-deoxy-D-glucose transport in adipose cell ghosts. 1973, Pubmed
D'Amato, Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. 1987, Pubmed
Donnelly, The need for ibogaine in drug and alcohol addiction treatment. 2011, Pubmed
Erreger, Currents in response to rapid concentration jumps of amphetamine uncover novel aspects of human dopamine transporter function. 2008, Pubmed
Ferrer, Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. 1998, Pubmed
Forrest, Identification of a chloride ion binding site in Na+/Cl -dependent transporters. 2007, Pubmed
Forrest, Mechanism for alternating access in neurotransmitter transporters. 2008, Pubmed
Forrest, The rocking bundle: a mechanism for ion-coupled solute flux by symmetrical transporters. 2009, Pubmed
Gorga, Equilibria and kinetics of ligand binding to the human erythrocyte glucose transporter. Evidence for an alternating conformation model for transport. 1981, Pubmed
Henderson, Factors affecting the inhibition of adenine nucleotide translocase by bongkrekic acid. 1970, Pubmed
Hilber, Serotonin-transporter mediated efflux: a pharmacological analysis of amphetamines and non-amphetamines. 2005, Pubmed
Humphreys, Ligand binding to the serotonin transporter: equilibria, kinetics, and ion dependence. 1994, Pubmed
Jacobs, Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter. 2007, Pubmed
Kahlig, Amphetamine induces dopamine efflux through a dopamine transporter channel. 2005, Pubmed
Keyes, Coupling of transmembrane proton gradients to platelet serotonin transport. 1982, Pubmed
Klingenberg, The ADP and ATP transport in mitochondria and its carrier. 2008, Pubmed
Korkhov, The conserved glutamate (Glu136) in transmembrane domain 2 of the serotonin transporter is required for the conformational switch in the transport cycle. 2006, Pubmed
Krishnamurthy, X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. 2012, Pubmed
Kristensen, SLC6 neurotransmitter transporters: structure, function, and regulation. 2011, Pubmed
Leal, Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors. 2003, Pubmed
Levi, A review of chemical agents in the pharmacotherapy of addiction. 2002, Pubmed
Lin, Single-channel currents produced by the serotonin transporter and analysis of a mutation affecting ion permeation. 1996, Pubmed , Xenbase
Loland, Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. 2008, Pubmed
Loland, Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding. 2004, Pubmed
Mager, Conducting states of a mammalian serotonin transporter. 1994, Pubmed , Xenbase
Martin, Kinetic and thermodynamic assessment of binding of serotonin transporter inhibitors. 2008, Pubmed
Nelson, Coupling between platelet 5-hydroxytryptamine and potassium transport. 1979, Pubmed
Pifl, Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. 1995, Pubmed
Reid, Neuropharmacological characterization of local ibogaine effects on dopamine release. 1996, Pubmed
Rice, Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. 2008, Pubmed
Sarker, The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter. 2010, Pubmed
Schicker, Unifying concept of serotonin transporter-associated currents. 2012, Pubmed
Scholze, The role of zinc ions in reverse transport mediated by monoamine transporters. 2002, Pubmed
Seidel, Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action. 2005, Pubmed
Shan, The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter. 2011, Pubmed
Shi, The mechanism of a neurotransmitter:sodium symporter--inward release of Na+ and substrate is triggered by substrate in a second binding site. 2008, Pubmed
Singh, Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. 2007, Pubmed
Singh, A competitive inhibitor traps LeuT in an open-to-out conformation. 2008, Pubmed
Sitte, Characterization of carrier-mediated efflux in human embryonic kidney 293 cells stably expressing the rat serotonin transporter: a superfusion study. 2000, Pubmed
Sonders, Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. 1997, Pubmed , Xenbase
Sucic, The N terminus of monoamine transporters is a lever required for the action of amphetamines. 2010, Pubmed , Xenbase
Tavoulari, Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes. 2009, Pubmed
Wall, Binding of the cocaine analog 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane to serotonin and dopamine transporters: different ionic requirements for substrate and 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane binding. 1993, Pubmed
Wells, The effects of ibogaine on dopamine and serotonin transport in rat brain synaptosomes. 1999, Pubmed
Yamashita, Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. 2005, Pubmed
Zhang, The cytoplasmic substrate permeation pathway of serotonin transporter. 2006, Pubmed
Zhang, Cysteine-scanning mutagenesis of serotonin transporter intracellular loop 2 suggests an alpha-helical conformation. 2005, Pubmed
Zhou, LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. 2007, Pubmed